A detailed history of Geode Capital Management, LLC transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 99,114 shares of ANVS stock, worth $590,719. This represents 0.0% of its overall portfolio holdings.

Number of Shares
99,114
Previous 76,233 30.01%
Holding current value
$590,719
Previous $439,000 81.78%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$5.27 - $15.46 $120,582 - $353,740
22,881 Added 30.01%
99,114 $798,000
Q2 2024

Aug 09, 2024

BUY
$4.82 - $18.01 $26,230 - $98,010
5,442 Added 7.69%
76,233 $439,000
Q1 2024

May 13, 2024

BUY
$8.47 - $18.93 $17,067 - $38,143
2,015 Added 2.93%
70,791 $842,000
Q4 2023

Feb 13, 2024

BUY
$5.55 - $19.62 $70,684 - $249,880
12,736 Added 22.73%
68,776 $1.29 Million
Q3 2023

Nov 13, 2023

BUY
$9.37 - $14.12 $41,134 - $61,986
4,390 Added 8.5%
56,040 $531,000
Q1 2023

May 15, 2023

BUY
$12.33 - $22.1 $99,774 - $178,833
8,092 Added 18.58%
51,650 $795,000
Q4 2022

Feb 13, 2023

BUY
$10.99 - $13.8 $13,869 - $17,415
1,262 Added 2.98%
43,558 $584,000
Q2 2022

Aug 12, 2022

BUY
$8.61 - $13.87 $2,316 - $3,731
269 Added 0.64%
42,296 $479,000
Q1 2022

May 13, 2022

BUY
$11.84 - $19.78 $12,810 - $21,401
1,082 Added 2.64%
42,027 $561,000
Q3 2021

Nov 12, 2021

BUY
$30.95 - $120.97 $73,537 - $287,424
2,376 Added 6.16%
40,945 $1.3 Million
Q2 2021

Aug 13, 2021

BUY
$21.55 - $96.1 $236,748 - $1.06 Million
10,986 Added 39.83%
38,569 $3.3 Million
Q1 2021

May 12, 2021

BUY
$8.15 - $38.44 $224,801 - $1.06 Million
27,583 New
27,583 $769,000

Others Institutions Holding ANVS

About Annovis Bio, Inc.


  • Ticker ANVS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 8,163,920
  • Market Cap $48.7M
  • Description
  • Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...
More about ANVS
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.